Smile-on News Logo

Smile-on News

Professional, Inspiring, Current

Healthcare Learning Logo

How many of your patients are suffering in silence?

How many of your patients are suffering in silence?

The GSK-supported ESCARCEL study, a pan-European epidemiology study on the prevalence of dentine hypersensitivity, has revealed significant insights into the condition. It exposed that more than 2 out of 5 young adults in Europe suffer from dentine hypersensitivity. Of those with the condition, 28.4% said the pain was important to them.1

Approximately 80% of sensitivity sufferers are not currently using a desensitising toothpaste.2 Over half of sufferers endure the symptoms in silence and fail to seek appropriate help from their dentist.3

Research into patients’ perspectives of dentine hypersensitivity reveals that patients experience a mixture of emotions about it. Patients have reported feeling anxiety, frustration and annoyance because of their sensitive teeth. The condition can cause sufferers to change their habits and avoid foods or drinks they may otherwise enjoy. There are too many patients that feel they must “just get on with it”.4

It’s important to recognise that some patients are suffering and that your recommendation could be their pathway to minimising their symptoms. Use of a desensitising toothpaste is a simple yet effective way to manage dentine hypersensitivity. Brushing twice daily should already be part of a patient’s oral health care routine so swapping to a desensitising toothpaste is an easy treatment plan to follow.

Sensodyne® products containing NovaMin® build a hydroxyapatite-like layer over and within exposed dentine tubules,5-9 repairing dentine to provide clinically proven sensitivity relief. The robust layer binds firmly to collagen in dentine7,10 and resists daily oral challenges, 5,7,9,11,12 helping to protect against the pain of dentine hypersensitivity with twice daily brushing.

To request FREE trial sized packs for your practice visit www.gsk-dentalprofessionals.co.uk.

 

References:

  1. West NX et al. J Dent 2013; 41: 1-11.
  2. GSK Data on File. March 2008.
  3. Addy M Int Dent J 2002; 52: 367-375.
  4. Gibson B et al. Dentistry 2010; 1: 11-21.
  5. Burwell A et al. J Clin Dent 2010; 21 (Spec Iss): 66-71.
  6. LaTorre G & Greenspan DC. J Clin Dent 2010; 21 (Spec Iss): 72-76.
  7. West NX et al. J Clin Dent 2011; 22 (Spec Iss): 82-89.
  8. Earl JS et al. J Clin Dent 2011; 22 (Spec Iss): 62-67.
  9. Earl JS et al. J Clin Dent 2011; 22 (Spec Iss): 68-73.
  10. Efflandt SE et al. J Mater Sci: Mater Med 2002; 13 (6): 557-565.
  11. Parkinson CR & Willson RJ. J Clin Dent 2011; 22 (Spec Iss): 74-81.
  12. Wang Z et al. J Dent 2010; 38: 400-410.

 

SENSODYNE, NOVAMIN and the rings device are registered trademarks of the GSK group of companies. 

comments powered by Disqus

Features

This month's special feature is:

Orthodontics


Newsletter

Sign up to our newsletter


Twitter